ArticleReviews in urology2007
Alpha blockers for the treatment of benign prostatic hyperplasia.
Article in Reviews in urology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07715448 ("Effect of Different Dosing Regimens of Tadalafil or Tamsulosin Combined With 5α-Reductase Inhibitors on Urinary and Sexual Outcomes in Benign Prostatic Hyperplasia), which is not on this map. Cited by 74 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
"Effect of Different Dosing Regimens of Tadalafil or Tamsulosin Combined With 5α-Reductase Inhibitors on Urinary and Sexual Outcomes in Benign Prostatic Hyperplasia: A Comparative Clinical Trial Study"
Who cites it
74 citing papers in PubMed, 4 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- Curcumin versus placebo in benign prostatic hyperplasia: a systematic review and meta-analysis.European journal of clinical pharmacology · 2026Pooled it
- Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2018Pooled it
- Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2017Pooled it
- Singapore Urological Association Clinical Guidelines for Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.Singapore medical journal · 2017Guideline
- Tadalafil versus tamsulosin as combination therapy with 5-alpha reductase inhibitors in benign prostatic hyperplasia, urinary and sexual outcomes.World journal of urology · 2024Trial
- A-blockers for the management of lower urinary tract symptoms in patients with prostate cancer treated with external beam radiotherapy: a randomized controlled study.World journal of urology · 2021Trial
- Pharmacokinetic bioequivalence studies of a fixed-dose combination of tamsulosin and dutasteride in healthy volunteers.Clinical drug investigation · 2014Trial
- The effect of first dose of tamsulosin on flow rate and its predictive ability on the improvement of LUTS in men with BPH in the mid-term.International urology and nephrology · 2013Trial
- A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.Indian journal of pharmacologyTrial
- Neurogenic lower urinary tract dysfunction in ageing men with spinal cord injury.Nature reviews. Urology · 2026Review
- Glymphatic function restored by α1-noradrenergic antagonism alleviates headache allodynia in mice.bioRxiv : the preprint server for biology · 2026Article
- Efficacy and safety of Serenoa repens in benign prostatic disorders: a systematic review of recent clinical evidence.Drugs in context · 2026Review
- Relevance of STIM/Orai Calcium Entry System Hyperactivation in Human Prostate Contractility in Benign Prostate Hyperplasia.International journal of molecular sciences · 2025Article
- The combination of water extracts ofNutrition research and practice · 2025Article
- Identifying progression subphenotypes of Alzheimer's disease from large-scale electronic health records with machine learning.Journal of biomedical informatics · 2025Article
- Alpha-1 antagonist treatment for eyelid retraction in patients with thyroid eye disease-a prospective pilot study.Eye (London, England) · 2025Article
- Management and Treatment of Benign Prostatic Hyperplasia Symptoms: Current Insights.Research and reports in urology · 2025Review
- Falls in a single brain rehabilitation center: a 3-year retrospective chart review.Frontiers in neurology · 2025Article
- Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists.Journal of the National Cancer Institute · 2024Article
- Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions.The Journal of pharmacology and experimental therapeutics · 2024Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The evolution of alpha blocker therapy for benign prostatic hyperplasia (BPH) has focused on improving convenience and tolerability. Indications for treating BPH include reversing signs and symptoms or preventing progression of the disease. The indication that most commonly drives the need for intervention is relief of lower urinary tract symptoms (LUTS) with the intent of improving quality of life. Alpha blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Four long-acting alpha 1 blockers are approved by the Food and Drug Administration for treatment of symptomatic LUTS/BPH: terazosin, doxazosin, tamsulosin, and alfuzosin. All are well tolerated and have comparable dose-dependent effectiveness. Tamsulosin and alfuzosin SR do not require dose titration. Alfuzosin, terazosin, and doxazosin have all been shown to be effective in relieving LUTS/BPH independent of prostate size.
Indexed as
Identifiers
18231614PMC2213889W134680794What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.